A Phase 2 interventional study of CEREDASE™ in Gaucher's Disease, sponsored by National Institute of Neurological Disorders and Stroke (NINDS). Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2016-09-22.
Sponsored by National Institute of Neurological Disorders and Stroke (NINDS) · Phase 2, Interventional, and Treatment
The purpose of this study is to examine how the skeleton responds to repeated doses of enzyme replacement therapy in patients with type I Gaucher's disease who have had their spleens removed.
Gaucher disease is a lysosomal storage disease resulting from glycocerebroside accumulation in macrophages due to a genetic deficiency of the enzyme glucocerebrosidase. It may occur in adults but occurs most severely in infants, in whom cerebroside also accumulates in neurons. Patients with Gaucher's disease experience enlargement of the liver and spleen and bone destruction. The condition is passed from generation to generation through autosomal recessive inheritance.
Type I is the most common form. It is a chronic non-neuronopathic form, meaning the disease does not affect nerve cells. The symptoms of type I can appear at any age.
In this study patients will be divided into three groups. Each group will receive different doses of enzyme replacement (Ceredase). In addition, two of the three groups will also receive doses of a form of vitamin D (calcitriol). Researchers believe the groups receiving vitamin D will have an improved response as compared to those patients only receiving enzyme replacement.
Patients in each group who respond to enzyme replacement with increases in bone density will be compared to the other treatment groups.
The purpose of this study is to examine the response of the skeleton to repeated infusions of macrophage-targeted glucocerebrosidase (CEREDASE (Trademark) ) in splenectomized patients with type I Gaucher's disease. The magnitude and rate of development of the skeletal response will be monitored non-invasively. Theoretically, an enhanced response should occur in patients supplemented with pharmacologic doses of 1, 25-dihydroxyvitamin D3 (calcitriol), since calcium absorption and enzyme delivery to bone marrow macrophages should be increased in this setting. These issues will be addressed in a clinical trial that uses a modified factorial design. A total of 57 patients will be assigned to three treatment groups by block randomization.
Group 1: CEREDASE (Trademark) (60 IU/kg q2wks; 0-6 months)
CEREDASE (Trademark) (30 IU/kg q2wks; 7-24 months)
Group 2: Calcitriol (0.25-3.0 micrograms/day; 0-24 months)
CEREDASE (Trademark) (60 IU/kg q2wks; 7-12 months)
CEREDASE (Trademark) (30 IU/kg q2wks; 13-24 months)
Group 3: Calcitriol (0.25-3.0 micrograms/day; 0-24 months)
CEREDASE (Trademark) (60 IU/kg q2wks; 0-6 months)
CEREDASE (Trademark) (30 IU/kg q2wks; 7-24 months)
The number of patients responding to enzyme replacement with a significant decrease in hepatic volume and a significant increase in trabecular bone density of the lumbar spine will be compared between the treatment groups.
171 studies on the registry are indexed under Gaucher Disease; 37 are open to participants now.
This study's enrollment of 100 is above the median of 20 across 98 interventional studies indexed under Gaucher Disease.
Browse Gaucher Disease studies →National Institute of Neurological Disorders and Stroke (NINDS) is the lead sponsor of 592 studies on the registry; 56 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 8 (44%) have results posted.
Counted across the registry records on this site, refreshed daily.
Splenectomized Gaucher patients.
Aged 18-45 who have not received enzyme therapy for at least 1 year.
No patients with other illnesses (pulmonary, liver, kidney, bone, hematologic).
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of Neurological Disorders and Stroke (NINDS)